TICKERNERD
Menu
AVBPAVBPHealthcare · Biotechnology

AVBP Stock Forecast: Arrivent BioPharma, Inc. Price Predictions for 2026-2027

Last close, 21 Oct 2026
$19
+1.64% on the day

The 11 Wall Street analysts covering Arrivent BioPharma, Inc. hold a median 12-month price target of $21 — +9.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 21 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$944.7M
Ticker Nerd rank
35/ 100
Median analyst target
$21
Analysts covering
11
Revenue$0.0
Operating income−$52.7M
Net income−$49.9M
Free cash flow−$39.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+18.3%
1M
−35.6%
YTD
−4.8%
1Y
−2.2%
From 52W high
−44.8%
From 52W low
+27.0%
$15
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVBP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arrivent BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
35/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
70
Volatility
61
Momentum
61
Growth
55
Quality
47
Size
44
Accruals
33
Issuance
29
Revisions
29

Value (70): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (29): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVBP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVBP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26AVBPHigh $29Median $21Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $15Median $21High $29

The green dot is the last close — the median target sits +9.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
20 Oct 2026B. Riley SecuritiesMaintainsBuy$45 → $29
16 Oct 2026BTIGReiteratesBuy$29
8 Oct 2026HC Wainwright & Co.MaintainsBuy$47 → $27
8 Oct 2026HC Wainwright & Co.MaintainsBuy—
7 Oct 2026BTIGMaintainsBuy—
7 Oct 2026BTIGMaintainsBuy$42 → $29
7 Oct 2026CitigroupMaintainsBuy$40 → $20
7 Oct 2026CitigroupMaintainsBuy—
7 Oct 2026GuggenheimMaintainsBuy—
7 Oct 2026GuggenheimMaintainsBuy$45 → $18
7 Oct 2026Jones TradingMaintainsBuy—
7 Oct 2026Jones TradingMaintainsBuy$45 → $22
7 Oct 2026Truist SecuritiesMaintainsBuy—
7 Oct 2026Truist SecuritiesMaintainsBuy$45 → $18
17 Aug 2026HC Wainwright & Co.MaintainsBuy—
17 Aug 2026HC Wainwright & Co.MaintainsBuy$44 → $47
13 Aug 2026BTIGReiteratesBuy—
13 Aug 2026BTIGReiteratesBuy$42
13 Aug 2026CitigroupMaintainsBuy—
13 Aug 2026CitigroupMaintainsBuy$43 → $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AVBP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

AVBP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Oct 2026, Arrivent BioPharma, Inc. returned −2.2% against +16.4% for the S&P 500, dividends included.

AVBP vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26AVBPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVBP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Arrivent BioPharma, Inc. (AVBP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.4×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.5×

Cheaper than 36% of US stocks

EV / EBITDA
−3.2×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−53.3%

Higher than 21% of US stocks

Return on assets
−33.1%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arrivent BioPharma, Inc. (AVBP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arrivent BioPharma, Inc. has a market value of $944.7M and an enterprise value of $570.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$163.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$147.9M.

  • Shares outstanding: 48.3M.

  • Trailing P/E: −4.4×; forward P/E: −5.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Arrivent BioPharma, Inc. employs 77 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

AVBP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVBPArrivent BioPharma, Inc.$944.7M35
MNKDMannKind Corp.$939.7M35
GLUEMonte Rosa Therapeutics, Inc.$947.9M66
JBIOJade Biosciences, Inc.$962.2M25
SGPSpyGlass Pharma, Inc.$923.2M2
SVRASavara, Inc.$918.4M34
CGEMCullinan Therapeutics, Inc.$915.1M70

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arrivent BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVBP news & analysis

ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop

Business Wire · 21 Oct 2026negative

Kirby McInerney LLP said it is investigating whether Arrivent BioPharma or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. The notice follows a reported 47.3% share drop and references the company’s October 6, 2026 disclosure about its Phase 3 FURVENT trial of firmonertinib; the excerpt provides no further trial details.

Why it matters — AVBP watchers may want to note the securities investigation announcement and its connection to the reported share decline and trial disclosure.

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

GlobeNewsWire · 19 Oct 2026positive

ArriVent announced publication in Cancer Cell of FURTHER Phase 1b results for firmonertinib in EGFR PACC-mutant non-small cell lung cancer. The publication highlights preclinical and clinical findings supporting the therapy’s potential, if approved, for treatment-naïve patients with advanced disease.

Why it matters — The publication draws attention to clinical findings for a company drug candidate being developed for a specific NSCLC population.

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

PRNewsWire · 13 Oct 2026negative

ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of its lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.

Why it matters — The trial result and investor-focused investigation are material developments for those following AVBP.

FAQ

Frequently asked questions about AVBP stock

What is the AVBP stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Arrivent BioPharma, Inc. have a median 12-month price target of $21, with estimates ranging from $15 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVBP stock a buy right now?

Of the 11 analysts covering Arrivent BioPharma, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrivent BioPharma, Inc. 35 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVBP?

As at 21 Oct 2026, Arrivent BioPharma, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (70 of 100).

Will AVBP stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +9.6% from the last close, and Ticker Nerd's factor model ranks Arrivent BioPharma, Inc. 35 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVBP stock forecast for 2030?

No analyst covering Arrivent BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $29 over the next 12 months.

How has AVBP stock performed over the past year?

Arrivent BioPharma, Inc. returned -2.2% over the 12 months to 21 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arrivent BioPharma, Inc. do?

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers.

What is the latest news on AVBP?

The most recent item we track (Business Wire, 21 Oct 2026): "ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop". Kirby McInerney LLP said it is investigating whether Arrivent BioPharma or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. The notice follows a reported 47.3% share drop and references the company’s October 6, 2026 disclosure about its Phase 3 FURVENT trial of firmonertinib; the excerpt provides no further trial details.

Company

About Arrivent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers. ArriVent BioPharma, Inc. concentrates on targeted oncology programs designed to address unmet medical needs, with particular emphasis on non-small-cell lung cancer and other solid tumors. Its current portfolio includes development of furmonertinib, an epidermal growth factor receptor mutant-selective therapy being evaluated across multiple EGFR mutation settings, as well as emerging pipeline candidates such as antibody-drug conjugates and other novel therapeutics. The company works through collaborations and in-licensing approaches to advance medicines from discovery into clinical development and, ultimately, patient access. Headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma, Inc. plays a specialized role in the oncology biopharmaceutical market by focusing on precision therapies for genetically defined cancer populations.

CEO Dr. Zhengbin Yao Ph.D. · 77 employees · United States · https://arrivent.com